Terumo ( (TRUMF) ) has released its Q1 earnings. Here is a breakdown of the information Terumo presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Terumo Corporation is a leading Japanese medical device company listed on the Tokyo Stock Exchange, specializing in cardiac and vascular solutions, medical care solutions, and blood and cell technologies.
In its latest earnings report for the three months ending June 30, 2025, Terumo Corporation reported a modest revenue increase of 0.7% year-on-year, reaching ¥259,965 million, with significant growth in operating profit and profit before tax.
Key financial highlights include a 25.2% increase in operating profit to ¥55,885 million and a 23.5% rise in profit for the period to ¥41,843 million. The company also reported a 15.7% increase in adjusted operating profit, driven by strong performance in the Cardiac and Vascular and Blood and Cell Technologies segments, despite challenges in the Medical Care Solutions segment.
The company’s financial position remains robust, with total assets at ¥1,799,436 million and a slight increase in total equity. Cash flow from operations was positive, although there was a decrease in cash and cash equivalents due to dividend payments and capital expenditures.
Looking ahead, Terumo Corporation maintains its financial guidance for the fiscal year ending March 31, 2026, focusing on expanding high value-added products and improving operational efficiencies amid a challenging global economic environment.